Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06770764RecruitingPhase 1
Testing ODC-IL2 for advanced solid tumors
This trial tests a new drug called ODC-IL2 for people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help your immune system fight cancer. The study starts with small doses to find the best dose, then expands to see how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06787014Recruiting
Surgery vs. no surgery for small intestinal NET with spread
This study looks at whether removing the main tumor in the small intestine (along with standard treatment) helps people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares this approach to treatment without surgery.
BernAges Any age - NCT06788938RecruitingPhase 2
Tarlatamab for advanced DLL3-positive tumors
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
Davis, CaliforniaAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06831461Recruiting
Proton vs photon radiation for brain tumors
This study compares two types of radiation therapy for adults with primary brain tumors that have a good outlook (expected survival longer than 5 years). You will receive either standard photon radiation or the more targeted proton radiation, to see if one works better or causes fewer side effects.
MumbaiAges 18–70 - NCT06840886RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+ - NCT06881992RecruitingPhase 3
Testing ersodetug for low blood sugar from neuroendocrine tumors
This study tests a new medicine called ersodetug in people whose neuroendocrine tumors cause dangerously low blood sugar that standard treatments can't control. If you need IV sugar or nutrition for at least a week, this trial may offer a new option to help manage your blood sugar.
Chicago, IllinoisAges 18 years+ - NCT06905015Recruiting
Comparing two methods to reduce blood loss during open liver surgery
This trial tests whether using stroke volume variation (SVV) is better than central venous pressure (CVP) to guide fluid management and reduce bleeding during open liver surgery. It aims to find a safer way to manage fluids during the operation.
Chiang Mai, ChiangmaiAges 20–70 - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06981455Recruiting
Life after surgery for neuroendocrine tumors
This study follows people after surgery to remove neuroendocrine tumors (NETs) from the stomach, intestines, or pancreas. It aims to understand long-term outcomes and quality of life.
Toronto, OntarioAges 18 years+ - NCT07056023Recruiting
Surgery and quality of life for spinal tumor patients
This trial studies how surgery for a type of spinal tumor (called a juxta-medullary tumor) affects your recovery and quality of life. Researchers want to learn from patients like you to improve care.
Münster, Nordrhien WestfalenAges 18 years+ - NCT07078136Recruiting
AI study for upper GI tumor diagnosis
This study uses artificial intelligence to help diagnose tumors in the upper stomach or esophagus. It looks at images from endoscopy and ultrasound to improve how doctors identify these growths.
Wuhan, HubeiAges 18 years+ - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07112989Recruiting
Building lab models for sarcoma and cancer spread
This study aims to create new laboratory models to better understand sarcomas and cancers that have spread to the bone or lungs. By using donated tumor tissue and blood, researchers hope to learn how these cancers grow and develop, which could lead to better treatments in the future.
BolognaAges Up to 85 years - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07169994RecruitingPhase 1/Phase 2
Testing YL202 with other cancer treatments for advanced solid tumors
This trial is testing a new drug called YL202 in combination with other anti-cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if this combination can shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07188441RecruitingPhase 2
Treating newly diagnosed central malignant germ cell tumors with teniposide and cisplatin
This trial tests a combination of two chemotherapy drugs—teniposide and cisplatin—for people who have just been diagnosed with a malignant germ cell tumor in the brain. The goal is to see if this treatment is safe and effective.
Guangzhou, GuangdongAges 5 years+ - NCT07224464Recruiting
Sarah Nanotechnology System for advanced solid tumors using heat therapy
This trial tests a new nanotechnology system that uses controlled heat to treat advanced solid tumors in the chest or abdomen that have not responded to standard treatments. It may be an option if you have few remaining choices and want to explore a novel approach.
Rochester, MinnesotaAges 18 years+ - NCT07243470RecruitingPhase 1/Phase 2
Tarlatamab and temozolomide for brain tumors
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
AngersAges 12 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.